CD1d-based combination therapy eradicates established tumors in mice | JoVE Visualize

Area of Science:

Immunology
Oncology
Cancer Therapy

Background:

Antibody-based therapies combined with immunostimulatory agents show promise for cancer treatment.
Previous work demonstrated efficacy of a three-mAb combination (anti-DR5, anti-CD40, anti-CD137) termed TriMab.
CD40 agonists present potential clinical toxicity, necessitating alternative strategies for immune cell activation.

Purpose of the Study:

To investigate a novel three-mAb combination (anti-DR5, anti-CD137, anti-CD1d), termed 1DMab, for cancer treatment.
To evaluate the efficacy of 1DMab in suppressing and eradicating established experimental tumors in mice.
To compare the efficacy of 1DMab with the previously studied TriMab and assess its potential in combination therapies.

Main Methods:

Utilized a combination of three monoclonal antibodies (mAbs): anti-DR5, anti-CD137, and anti-CD1d (1DMab).
Tested 1DMab therapy in mouse models of established renal, breast, and colon carcinomas.
Assessed the requirement for specific immune cells (CD8(+) T cells, NK cells) and cytokines (IFN-gamma, IL-12) for 1DMab efficacy.
Compared 1DMab efficacy against TriMab in different tumor microenvironments.

Main Results:

1DMab therapy suppressed and/or eradicated established experimental renal, breast, and colon carcinomas in mice.
Tumor suppression by 1DMab required CD8(+) T cells, IFN-gamma, and CD1d, with partial requirement for NK cells and IL-12.
1DMab was more effective than TriMab in models involving CD1d-restricted type II NKT cells but less effective where regulatory T cells were critical.
Anti-CD1d mAbs showed potential efficacy when combined with anti-CD137 and conventional chemotherapeutics.

Conclusions:

This study demonstrates the antitumor activity of a novel combination of anti-DR5, anti-CD137, and anti-CD1d mAbs (1DMab).
1DMab therapy represents a viable alternative to potentially toxic CD40 agonists for cancer immunotherapy.
Rational combination chemoimmunotherapies based on tumor immunoregulation, particularly involving anti-CD1d mAbs, may enhance treatment efficacy.